Jasper Bos, PhD
Jasper Bos joined Merck’s previous biopharma fund of M Ventures in 2009 and transitioned to Senior Vice President and Managing Director M Ventures in 2019. At M Ventures, Jasper Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Luendbeck for close to $1,100 Billion, Calypso Biotech, Inthera, Metabomed and Asceneuron. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute. Jasper published over 35 articles on health economics, vaccines and mathematical modelling.
Francois Conquet, PhD
François Conquet defended his PhD in 1991, at the Pasteur Institute in Paris and did his Post-doc at Genentech. After that, he joined the GSK Research Institute of Geneva where he worked as a scientist in CNS research until 2001. Then, he left GSK to found Addex Pharmaceuticals in Geneva, where he stayed CEO until 2005. Addex is a Biotech company dedicated to the discovery of novel treatments for CNS diseases. Then, he joined Merck Serono as Director, Early Stage Licensing. In April 2012, at the closing of the Geneva site of Merck Serono, François founded Prexton Therapeutics as CEO. Prexton was a biotech dedicated to the development of an mGluR4 compound for Parkinson’s disease. Prexton raised 41M€ from 2012 until 2018. In March 2018, Prexton has been acquired by Lundbeck for 905M€.